Anthem Biosciences IPO Marathi News: Anthem Biosciences Limited’s Rs 3395 crore IPO has become a center of attraction for investors. The issue is closing on July 16, 2025 and has started receiving a good response in the first two days. On the first day, its subscription was 0.77 times, while on the second day it increased to 3.48 times. But the real boom was seen on the last day, when the issue was subscribed a total of 10.47 times till 12:34 pm.

If we talk about investor classes, retail investors subscribed 3.95 times, while non-inastitutional investors (NIIs) gave full support with a subscription of 27.65 times. Qualified Institutional Buyers (QIBs) also subscribed 9.05 times, which clearly shows that institutional investors are also showing confidence in the issue.

Not only in the primary market, but Anthem Biosciences’ IPO is also in the news in the unlisted market, i.e. the grey market. Its shares are showing a grey market premium (GMP) of Rs 153, which is about 26.8% higher than its cap price. At one point, its GMP has also reached Rs 156, while on the first day of the issue, it was around Rs 116.

Anthem Biosciences Limited is a leading CRDMO company covering the entire life cycle of New Chemical Entity (NCE) and New Biological Entity (NBE). The company works on advanced platforms such as RNAi, ADC, peptides, lipids, oligonucleotides and enzymatic processes. In addition, it also manufactures API products such as probiotics, enzymes, nutritional actives and biosimilars.

Talking about financial performance, the company has registered tremendous growth during the financial years ended March 31, 2024 to March 31, 2025. During this period, the company’s revenue grew by 30% and profit after tax (PAT) by 23%. In the financial year 2025, the company reported revenue of Rs 1930.29 crore and profit of Rs 451.26 crore, which is a reflection of its strong business model and efficiency.